SpringWorks Therapeutics Inc
NASDAQ:SWTX
SpringWorks Therapeutics Inc
Cash from Operating Activities
SpringWorks Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
SpringWorks Therapeutics Inc
NASDAQ:SWTX
|
Cash from Operating Activities
-$222.8m
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is SpringWorks Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-222.8m
USD
Based on the financial report for Dec 31, 2023, SpringWorks Therapeutics Inc's Cash from Operating Activities amounts to -222.8m USD.
What is SpringWorks Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-74%
Over the last year, the Cash from Operating Activities growth was -38%. The average annual Cash from Operating Activities growth rates for SpringWorks Therapeutics Inc have been -91% over the past three years , -74% over the past five years .